Aquestive Therapeutics, Inc. AQST AQST-108 project expenses — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s aqst-108 project expenses — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s AQST-108 project expenses — R&D?
- Aquestive Therapeutics, Inc. (AQST) reported AQST-108 project expenses — R&D of $558K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s AQST-108 project expenses — R&D changed year-over-year?
- Aquestive Therapeutics, Inc.'s AQST-108 project expenses — R&D increased by 186.2% year-over-year, from $195K to $558K.
- What does AQST-108 project expenses — R&D mean?
- This metric represents the direct research and development expenditures specifically allocated to the AQST-108 pharmaceutical development project. It captures the costs associated with clinical trials, formulation development, and regulatory activities required to advance this specific therapeutic candidate toward commercialization. Monitoring these expenses provides insight into the company's capital allocation strategy and the progress of its pipeline toward potential market entry.